

Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in *Apc*^{Δ716} mice involves stromal COX-2

Teruaki Fujishita,¹ Rie Kajino-Sakamoto,¹ Yasushi Kojima,¹ Makoto Mark Taketo² and Masahiro Aoki¹

¹Division of Molecular Pathology, Aichi Cancer Center Research Institute, Nagoya; ²Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Key words

Adenomatous polyposis coli, chemokine CCL2, colorectal neoplasms, cyclooxygenase 2, extracellular signal-regulated MAP kinases

Correspondence

Masahiro Aoki, Division of Molecular Pathology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-Ku, Nagoya, Aichi 464-8681, Japan.
Tel: +81-52-762-6111; Fax: +81-52-763-5233;
E-mail: msaoki@aichi-cc.jp

Funding Information

Japan Society for the Promotion of Science (Kakenhi) (24790382, 26290045); Yasuda Medical Foundation; Suzuken Memorial Foundation; Takeda Science Foundation.

Received January 2, 2015; Revised March 23, 2015;
Accepted April 3, 2015

Cancer Sci 106 (2015) 692–699

doi: 10.1111/cas.12670

Extracellular signal-regulated kinase is an MAPK that is most closely associated with cell proliferation, and the MEK/ERK signaling pathway is implicated in various human cancers. Although epidermal growth factor receptor, KRAS, and BRAF are considered major targets for colon cancer treatment, the precise roles of the MEK/ERK pathway, one of their major downstream effectors, during colon cancer development remain to be determined. Using *Apc*^{Δ716} mice, a mouse model of familial adenomatous polyposis and early-stage sporadic colon cancer formation, we show that MEK/ERK signaling is activated not only in adenoma epithelial cells, but also in tumor stromal cells including fibroblasts and vascular endothelial cells. Eight-week treatment of *Apc*^{Δ716} mice with trametinib, a small-molecule MEK inhibitor, significantly reduced the number of polyps in the large size class, accompanied by reduced angiogenesis and tumor cell proliferation. Trametinib treatment reduced the COX-2 level in *Apc*^{Δ716} tumors *in vivo* and in primary culture of intestinal fibroblasts *in vitro*. Antibody array analysis revealed that trametinib and the COX-2 inhibitor rofecoxib both reduced the level of CCL2, a chemokine known to be essential for the growth of *Apc* mutant polyps, in intestinal fibroblasts *in vitro*. Consistently, trametinib treatment reduced the *Ccl2* mRNA level in *Apc*^{Δ716} tumors *in vivo*. These results suggest that MEK/ERK signaling plays key roles in intestinal adenoma formation in *Apc*^{Δ716} mice, at least in part, through COX-2 induction in tumor stromal cells.

Colorectal cancer is one of the leading causes of cancer-related deaths, and its progression is considered to involve various genetic and epigenetic changes.

Heterozygous *Apc* mutant mice develop adenomatous polyps in the intestines, and are widely used as a genetically-engineered model of familial adenomatous polyposis and early-stage sporadic colon cancer.⁽¹⁾ Loss of heterozygosity at *Apc* loci in intestinal epithelial cells of the *Apc* mutant mice leads to Wnt signaling activation, resulting in tumor initiation in the intestines.⁽²⁾ However, activation of Wnt signaling is not sufficient for tumor formation; we and others reported earlier that the growth of intestinal tumors in *Apc* mutant mice required induction of COX-2 in tumor stromal cells and activation of mammalian target of rapamycin complex 1 (mTORC1) in tumor epithelial cells.^(3–7) We subsequently found that JNK activation in adenoma epithelial cells of *Apc* mutants was responsible for mTORC1 activation and hence tumor formation.⁽⁸⁾

The MAPK family consists of ERK, JNK, and p38 MAPK, and ERK is most closely implicated in the regulation of cell proliferation and survival, as well as in oncogenic transformation.^(9,10) In colorectal cancer, epidermal growth factor receptor, KRAS, and BRAF are considered major targets for therapy, and MEK/ERK is one of their important downstream effectors. However, the roles of the MEK/ERK signaling in

the formation of intestinal adenomas prior to the acquisition of KRAS or BRAF mutations are not fully understood.

Trametinib is an allosteric inhibitor of MEK1/2,^(11,12) and has been approved by the FDA for treating patients with metastatic melanoma harboring the *BRAF*^{V600E/K} mutation.^(9,10) Here we show that treatment with trametinib suppresses the growth of intestinal polyps in *Apc*^{Δ716} mice. Activation of ERK was observed not only in a subset of adenoma epithelial cells, but also in stromal cells including fibroblasts and vascular endothelial cells, and trametinib treatment reduced the levels of COX-2 in tumors *in vivo* and intestinal fibroblasts *in vitro*, suggesting a role for stromal MEK/ERK signaling in intestinal tumor formation.

Materials and Methods

Animals and drug treatments. The construction of *Apc*^{Δ716} mice was described previously.⁽²⁾ Male and female *Apc*^{Δ716} mice at 10 weeks of age were gavaged with trametinib (2 mg/kg/day; LC Laboratories, Woburn, MA, USA) or vehicle (2% acetic acid, 10% polyoxyethylene(10) castor oil, and 10% PEG400) for 8 weeks.⁽¹²⁾

All animal experiments were carried out according to the protocols approved by the Animal Care and Use Committee of Aichi Cancer Center Research Institute (Nagoya, Japan).

Microvessel density. Microvessel density was determined as described previously.⁽⁵⁾

Western blot analysis. Western blot analysis was carried out as described previously,⁽⁵⁾ using primary antibodies for β -actin (Sigma-Aldrich, St. Louis, MO), phosphorylated p-S6, p-Akt,

p-ERK1/2, p-JNK, p-p38, p-STAT3, COX-1 (Cell Signaling Technology, Danvers, MA, USA), and COX-2 (Cayman Chemical, Ann Arbor, MI, USA).

Angiogenesis antibody array analysis. Primary mouse intestinal fibroblasts were serum-starved with 0.1% FBS for 12 h,




Fig. 1. Activation of ERK in intestines of WT and *Apc*^{Δ716} mice. (a) Western blot analysis for ERK phosphorylation in various parts of the intestines of WT C57BL/6 mice treated with trametinib or vehicle (control). Col, colon; Duo, duodenum; Ile, ileum; Jej, jejunum. (b) Immunostaining of p-ERK in intestines of WT mouse treated with trametinib or vehicle (control) for 1 week. Lower panels of each section show higher magnification of the boxed areas in the corresponding upper panels. Bar = 50 μ m. (c) Western blot analysis for effects of trametinib treatment on signaling pathways in the ileum of WT mouse. (d) Western blot analysis for effects of trametinib treatment on signaling pathways in normal intestinal mucosa (N) and polyps (P) of *Apc*^{Δ716} mouse. (e) Immunostaining of p-ERK in intestinal polyps of *Apc*^{Δ716} mouse treated with trametinib or vehicle (control) for 1 week. Lower panels show higher magnifications of the boxed areas in the upper panels. Bars, upper panels = 200 μ m; lower panels = 50 μ m.

then cultured in DMEM with 10% FBS in the presence of trametinib (10 nM), rofecoxib (10 μ M; Sigma), or vehicle control (DMSO) for 16 h. Preparation of whole cell lysates and antibody array analysis was carried out according to the manufacturer's protocol (Mouse Angiogenesis Array Kit, ARY015; R&D Systems, Minneapolis, MN).

Statistical analysis. Statistical analyses were carried out using R (version 3.0.2; R Foundation for Statistical Computing, Vienna, Austria) with the EZR package (version 1.20; Saitama Medical Center, Jichi Medical University, Saitama, Japan).⁽¹³⁾ Values of $P < 0.05$ were considered significant.

Details on histological analysis and immunohistochemistry, immunofluorescence analysis, BrdU staining, RT-PCR analysis, and primary culture of intestinal fibroblasts are provided in Data S1.

Results

Activation status of ERK in normal intestines and intestinal polyps of *Apc* ^{Δ 716} mice. To study the roles of MEK/ERK signaling in intestinal polyp formation, we first determined the ERK activation status in normal intestines of WT C57BL/6 mice and intestinal adenomatous polyps in *Apc* ^{Δ 716} mice. Western blot analysis with a p-ERK antibody showed ERK activation in the intestines of WT mice, with weaker activation in the colon compared with the small intestine (Fig. 1a). Immunohistochemical analysis showed marked ERK phosphorylation in

intestinal epithelial cells of the crypts, which was stronger in the proximal parts of the small intestine, namely the duodenum and jejunum, as compared with the ileum and colon (Fig. 1b). The ERK phosphorylation levels in intestinal stromal cells did not differ significantly in the proximal–distal axis of the intestines. One-week treatment of the WT mice with the MEK inhibitor trametinib greatly reduced the phosphorylation levels of ERK, but not those of JNK, p38 MAPK, STAT3, Akt, or S6, suggesting efficient and specific inhibition of the MEK/ERK pathway in the intestines by trametinib with minimal effects on the JNK, p38 MAPK, JAK–STAT, PI3K–Akt, or mTOR pathways (Fig. 1a–c). Western blot analysis using samples from 10-week old *Apc* ^{Δ 716} mice showed similar levels of ERK phosphorylation between the normal intestinal mucosa and intestinal tumors (Fig. 1d). JNK signaling was activated in the tumors, whereas PI3K and p38 MAPK pathways were not, as we reported previously.⁽⁸⁾ Although ERK phosphorylation was observed in tumor epithelial cells near the luminal side, it was more prominent in tumor stromal cells (Fig. 1e). One-week treatment of *Apc* ^{Δ 716} mice with trametinib significantly reduced the ERK phosphorylation level in the polyps (Fig. 1d, e). Trametinib treatment induced a mild increase in the p38 MAPK phosphorylation level in the polyps; the molecular mechanisms and biological significance underlying this observation are currently unknown.

To identify stromal cell types that showed MEK/ERK activation in the intestinal polyps of *Apc* ^{Δ 716} mice, we next carried




Fig. 2. Co-immunostaining analyses for p-ERK and markers of stromal cells. Immunofluorescence staining for p-ERK and vimentin (left panels, mesenchymal cell marker), CD34 (middle panels, vascular endothelial cell marker), and α -smooth muscle actin (α -SMA) (right panels, a myofibroblast marker) in small intestinal polyps of *Apc* ^{Δ 716} mice using confocal laser scanning microscopy ($\times 64$). Nuclei are stained with DAPI (blue). Top panels show merged images with p-ERK in green, stromal cell markers in red, and DAPI in blue. Arrows indicate cells that are double-positive for p-ERK and stromal cell markers.

out co-immunostaining with the p-ERK antibody and antibodies against markers of some stromal cell types, specifically vimentin (a mesenchymal cell marker), CD34 (a vascular endothelial cell marker), α -smooth muscle actin (α -SMA; a myofibroblast marker), β -tubulin III (a neuronal cell marker), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1; a lymphatic endothelial cell marker), and CD45 (a leucocyte marker) (Figs 2,S1,S2). Although only a small fraction (<10%) of vimentin, CD34, or α -SMA positive cells showed co-staining for p-ERK in the normal intestinal mucosa (Fig. S1), a good percentage (>60%) of them showed co-staining in the polyps, especially in their luminal side (Figs 2,S1). The cells co-stained with both vimentin and p-ERK showed spindle-shaped morphology and their frequency was much higher than that of other specified stromal cells, which suggest that those cells are likely fibroblasts, although they are difficult to positively identify due to the lack of specific marker antibodies. We observed some stromal cells co-stained for p-ERK with β -tubulin III or LYVE-1. However, the frequency of β -tubulin III-positive or LYVE-1-positive cells was extremely low in the polyps (<10 per polyp section, as compared with >100 for vimentin-positive cells) and their significance is thus unknown (Figs S1,S2). Co-staining for p-ERK and CD45 was rarely observed in the polyps (Figs S1,S2). These results suggest that p-ERK-positive stromal cells in the *Apc* ^{Δ 716} polyps mainly include vascular endothelial cells, myofibroblasts, and probably fibroblasts.

Trametinib treatment inhibits polyp formation in *Apc* ^{Δ 716} mice. To determine whether MEK/ERK signaling was involved in intestinal tumor formation, we then treated *Apc* ^{Δ 716} mice with trametinib for 8 weeks from 10 to 18 weeks of age (Fig. 3a).

As shown in Figure 3(b,c), trametinib treatment significantly reduced the number of intestinal polyps in the large size class ($\Phi \geq 1.5$ mm). Polyps in trametinib-treated *Apc* ^{Δ 716} mice showed a collapsed morphology at the top (Fig. 3d), similarly to the polyps of *Apc* ^{Δ 716} mice in which COX-2 or mTORC1 was inhibited.^(3,5,8)

To study the mechanism of inhibition of polyp formation by trametinib, we next evaluated cell proliferation rate by BrdU incorporation assay. Treatment with trametinib significantly reduced the BrdU labeling index of adenoma epithelial cells, whereas no change was observed in that of normal intestinal epithelial cells (Fig. 4a,b). Activation of ERK in tumor vascular endothelial cells (Fig. 2) suggests the possibility that MEK inhibition may affect tumor angiogenesis. We thus examined the effects of trametinib treatment on angiogenesis in *Apc* ^{Δ 716} intestinal polyps. Eight-week treatment significantly reduced the microvessel density in the polyps (Fig. 4c,d). These results suggest that trametinib treatment may suppress tumor formation in *Apc* ^{Δ 716} mice by inhibiting tumor cell proliferation and angiogenesis.

Trametinib treatment reduces levels of COX-2 and CCL2 in *Apc* ^{Δ 716} polyps. Stromal COX-2 has been implicated in intestinal polyp formation in *Apc* ^{Δ 716} mice through regulation of angiogenesis.⁽¹⁴⁾ We next determined the effects of trametinib treatment on COX-2 expression levels. Western blot analysis showed that expression of COX-2, but not COX-1, was induced in *Apc* ^{Δ 716} polyps as reported previously,⁽³⁾ and that the COX-2 induction was suppressed dramatically by 1-week treatment with trametinib (Fig. 5a). Real-time RT-PCR analysis revealed that trametinib significantly decreased the COX-2 mRNA level in polyps (Fig. 5b). To address the possible roles




Fig. 3. Trametinib treatment suppresses adenoma formation in *Apc* ^{Δ 716} mice. (a) Schematic diagram of the trametinib treatment schedule for *Apc* ^{Δ 716} mice. (b) Gross appearance of intestinal polyps in *Apc* ^{Δ 716} mice treated with vehicle (control) or trametinib. (c) Number of polyps in the large-size ($\Phi \geq 1.5$ mm) and small-size ($\Phi < 1.5$ mm) classes in *Apc* ^{Δ 716} mice treated with vehicle (control, $n = 5$) or trametinib ($n = 6$). Data are average $\pm$ SD, and statistical significance was assessed by Student's *t*-test. * $P < 0.05$. (d) H&E staining of adenomatous polyps in *Apc* ^{Δ 716} mouse treated with vehicle (control) or trametinib. Bar = 200 μ m.

of the MEK/ERK signaling in COX-2 expression, we then examined localization of the COX-2 expressing cells and the cells positive for p-ERK staining in the polyps. As co-staining was not possible, we carried out immunohistochemical analysis using serial sections, which showed a similar staining pattern for p-ERK and COX-2 (Fig. 5c). Previous studies that showed the critical role of COX-2 in intestinal polyp formation in *Apc*^{Δ716} mice identified stromal fibroblasts and vascular endothelial cells as the main cell types that expressed COX-2 in their tumors.⁽⁴⁾ Because intestinal vascular endothelial cells were difficult to isolate for primary cultures, we examined the effects of trametinib treatment on COX-2 expression using primary culture of fibroblasts prepared from the intestines of ~8-week-old WT mice. Trametinib treatment strongly suppressed COX-2 induction by serum stimulation at both protein and mRNA levels (Fig. 5d,e), suggesting the requirement of MEK/ERK signaling for COX-2 expression in intestinal fibroblasts. To gain insights into the possible mechanisms by which MEK/ERK signaling may contribute to tumor angiogenesis and tumor growth through COX-2 induction in intestinal fibroblasts, we carried out angiogenesis antibody array analysis using lysates of intestinal fibroblasts treated with rofecoxib or trametinib. As shown in Figure 5(f), treatment with rofecoxib or trametinib markedly reduced the level of CCL2 (MCP-1) as compared with vehicle control. Moreover, the mRNA level of *Ccl2* was markedly elevated in the intestinal polyps of *Apc*^{Δ716} mice, which was greatly reduced by trametinib treatment (Fig. 5g). Taken together, these results suggest the possibility that the MEK/ERK signaling positively regulates CCL2 expression through COX-2 induction in intestinal fibroblasts,

which may help to promote angiogenesis and hence the growth of *Apc*^{Δ716} polyps.

Discussion

In the present study, we have shown that the MEK inhibitor trametinib suppresses formation of intestinal adenomas in *Apc*^{Δ716} mice, and propose that the antitumor effect of trametinib is at least in part mediated by its ability to suppress COX-2 induction in the tumor microenvironment. First, we have shown ERK activation not only in some tumor epithelial cells, but also in vascular endothelial cells, myofibroblasts, and vimentin-positive mesenchymal cells (likely fibroblasts) in the tumor stroma (Figs 1b,c,2,S1,S2). Second, trametinib treatment greatly reduced the COX-2 levels in *Apc*^{Δ716} polyps *in vivo*, as well as in primary culture of fibroblasts prepared from mouse intestines *in vitro* (Fig. 5). Our previous studies on *Apc*^{Δ716} mice clarified essential roles of COX-2 induction in intestinal tumor formation,^(3,15,16) and identified fibroblasts and vascular endothelial cells as major producers of COX-2 in the intestinal polyps.⁽⁴⁾ In this study, we have observed overlapped staining patterns for p-ERK-positive and COX-2-positive cells in serial sections of the luminal side of the polyps where most of the COX-2-expressing cells resided. Consistently, many vascular endothelial cells and fibroblasts were found in the luminal side of the polyps (Fig. S1).

Regarding the roles of ERK in intestinal tumor formation in *Apc* mutant mice, Lee *et al.*⁽¹⁷⁾ reported that intestinal microflora activated ERK in intestinal tumor epithelial cells of *Apc*^{Min} mice through MyD88, a key signaling molecule




Fig. 4. Trametinib attenuates adenoma cell proliferation and angiogenesis. (a) Micrographs of normal intestinal mucosa and adenoma epithelium labeled with BrdU in *Apc*^{Δ716} mice treated with vehicle (control) or trametinib for 8 weeks. Bar = 50 μm. (b) BrdU labeling indices of normal intestinal mucosa and adenoma epithelium in *Apc*^{Δ716} mice treated with vehicle (control) or trametinib. Data are average ± SD, and statistical significance was assessed by one-way ANOVA and Tukey's test. **P* < 0.05. (c) Immunostaining of CD34 in a small intestinal polyp of vehicle-treated (left) and trametinib-treated (right) *Apc*^{Δ716} mice. Bar = 50 μm. (d) Microvessel density in polyps of vehicle-treated (left) or trametinib-treated (right) *Apc*^{Δ716} mice. Data are average ± SD, and statistical significance was assessed by Student's *t*-test. ***P* < 0.01.




Fig. 5. Trametinib treatment reduces COX-2 levels in polyps and stromal fibroblasts of *Apc*^{Δ716} mice. (a) Western blot analysis for COX-2 and COX-1 in normal intestinal mucosa (N) and polyps (P) of *Apc*^{Δ716} mice treated with vehicle (control) or trametinib for 1 week. (b) Expression of COX-2 analyzed by real-time RT-PCR in normal intestinal mucosa and polyps of *Apc*^{Δ716} mice treated with vehicle (control) or trametinib for 1 week. Fold changes in expression levels were determined relative to the levels in normal intestinal mucosa of vehicle-treated mice. Data are average $\pm$ SD, and statistical significance was assessed by one-way ANOVA and Tukey's test. $*P < 0.05$. (c) Immunostaining of p-ERK and COX-2 in ileal polyps of *Apc*^{Δ716} mouse. Bar = 20 μ m. (d) Western blot analysis of COX-2, COX-1, and MAPKs in primary cultures of intestinal fibroblasts prepared from ~8-week-old WT mice. Serum-starved cells were stimulated with serum in the presence or absence of trametinib (at 2 or 20 nM). (e) Expression of COX-2 analyzed by real-time RT-PCR in primary cultures of intestinal fibroblasts treated as in (d). Fold changes in expression levels were determined relative to the levels in the cells stimulated with 10% FBS in the absence of trametinib (control). Data are average $\pm$ SD, and statistical significance was assessed by one-way ANOVA and Tukey's test. $*P < 0.05$. (f) Angiogenesis antibody array analysis of primary intestinal fibroblasts. Serum-starved cells were stimulated with serum in the presence of vehicle control (DMSO), rofecoxib (10 μ M), or trametinib (10 nM). (g) Semiquantitative RT-PCR analysis of *Ccl2* expression in normal intestinal mucosa (N) and polyps (P) of *Apc*^{Δ716} mice treated with vehicle (control) or trametinib for 1 week.

downstream of Toll-like receptors. They further showed that the activated ERK phosphorylated and thereby stabilized c-Myc protein in tumor epithelial cells, leading to promotion of the tumor growth.⁽¹⁷⁾ In the study they showed suppression of tumor formation in *Apc*^{Min} mice by treatment with the MEK1 inhibitor PD98059, consistent with our finding using trametinib. Although our present work suggests the roles of the MEK/ERK signaling in tumor microenvironment, in contrast to its direct role in tumor epithelial cells as suggested by Lee *et al.*, the two proposed mechanisms are not mutually exclusive and may co-operate in promoting tumor formation. The upstream signaling that activates ERK also remains to be clarified. Lee *et al.*⁽¹⁷⁾ claimed the importance of intestinal bacteria in activating ERK through MyD88 in intestinal epithelial cells. However, experiments using germ-free mice or antibiotic treatment showed mixed results as to the roles of intestinal microflora in tumor formation in *Apc* mutant mice,^(18–22) with some reports suggesting their limited roles in tumor formation.

Angiogenesis antibody array analysis identified CCL2 (also known as MCP-1) as a candidate molecule regulated by both MEK/ERK signaling and COX-2 in intestinal fibroblasts (Fig. 5f). CCL2 is a pro-inflammatory chemokine that has been implicated in monocyte recruitment, angiogenesis, and development of tumor microenvironment.⁽²³⁾ Previous studies by others showed that *Ccl2* was highly expressed in the polyps of *Apc*^{Min} mice,⁽²⁴⁾ and that *Ccl2* deficiency significantly reduced the number of intestinal polyps, especially that of large polyps, in *Apc*^{Min} mice.⁽²⁵⁾ We confirmed elevated *Ccl2* mRNA levels in the polyps of *Apc*^{Δ716} mice, which were markedly reduced by trametinib treatment (Fig. 5g), suggesting the possibility that the MEK/ERK signaling activation in stromal fibroblasts may promote tumor angiogenesis in part by positively regulating COX-2 and CCL2. We also observed co-staining of p-ERK and vascular endothelial cells in intestinal tumors (Fig. 2). MEK/ERK signaling has been implicated in angiogenesis;⁽²⁶⁾ for instance, the MEK1 inhibitor selumetinib was shown to suppress the growth of non-small cell lung cancer

xenografts, accompanied by decreased microvessel density.⁽²⁷⁾ The antiangiogenic activity of trametinib could thus be combination of direct effects on endothelial cells and indirect effects mediated by reduced expression of COX-2 in fibroblasts.

The mechanisms by which MEK/ERK signaling positively regulates COX-2 in stromal fibroblasts and vascular endothelial cells of *Apc*^{Δ716} polyps are currently unknown. Expression of COX-2 is regulated at the transcriptional and post-transcriptional levels,⁽²⁸⁾ and ERK has been implicated in both levels of control in fibroblasts.^(29–31) The molecular mechanism of the MEK/ERK activation in the tumor stroma are also not clear. Further studies will elucidate the molecular mechanisms underlying COX-2 induction by MEK/ERK signaling in tumor stromal fibroblasts.

Trametinib has been approved for treating metastatic melanoma patients with BRAFV600E/K mutations.^(9,10,32) Studies on metastatic melanoma patients with BRAFV600E/K mutations showed that combination treatment with the BRAF inhibitor dabrafenib and trametinib had better efficacy than single dabrafenib treatment, and also induced less skin toxicity, with decreased numbers of patients developing hyperkeratosis or skin papillomas.⁽³³⁾ A recent report showed that COX-2 inhibition can prevent the appearance of keratoacanthomas and cutaneous squamous cell carcinomas after treatment with BRAF inhibitors in a mouse model.⁽³⁴⁾ The beneficial effects of trametinib when combined with BRAF inhibitors thus may, in part, be through its effect on reducing COX-2 levels. Clinical

trials are underway for treatment of colorectal cancers using multiple kinase inhibitors including trametinib and dabrafenib (Clinical-Trials.gov identifiers NCT01750918 and NCT01902171), in which the ability of trametinib to reduce COX-2 levels may also be beneficial.

In conclusion, we have shown that MEK/ERK signaling is activated in some tumor epithelial cells and stromal cells in the intestinal polyps of *Apc*^{Δ716} mice, and that the MEK inhibitor trametinib potently suppresses tumor formation, accompanied by reduced COX-2 induction in the tumor stroma. These results also suggest that trametinib, a drug that is already approved for treating a subset of melanoma patients, may be useful for prevention of colonic polyp formation in familial adenomatous polyposis patients with *APC* mutations.

Acknowledgments

This work was supported by the Japan Society for the Promotion of Science (Kakenhi grant no. 24790382 to T.F. and grant no. 26290045 to M.A.). This research was also supported by The Yasuda Medical Foundation, Suzuken Memorial Foundation (to T.F.), and Takeda Science Foundation (to M.A.). The authors thank R. Mitsuya, Y. Fuma, and Y. Goto for their technical assistance.

Disclosure Statement

The authors have no conflict of interest.

References

- 1 Aoki M, Taketo MM. Use of genetically engineered mouse models in identification and validation of therapeutic targets for colon cancer. In: Goss KH, Kahn M, eds. *Targeting the Wnt Pathway in Cancer*. New York: Springer, 2011; 143–63.
- 2 Oshima M, Oshima H, Kitagawa K *et al*. Loss of *Apc* heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated *Apc* gene. *Proc Natl Acad Sci U S A* 1995; **92**: 4482–6.
- 3 Oshima M, Dinchuk JE, Kargman SL *et al*. Suppression of intestinal polyposis in *Apc*^{Δ716} knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* 1996; **87**: 803–9.
- 4 Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. *Cancer Res* 2001; **62**: 6848–9.
- 5 Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in *Apc*^{Δ716} mice. *Proc Natl Acad Sci U S A* 2008; **105**: 13544–59.
- 6 Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, Kunzelmann K. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in *APC*^{Min/+} mice. *Oncogene* 2010; **29**: 1553–60.
- 7 Metcalfe C, Ibrahim AE, Graeb M *et al*. Dvl2 promotes intestinal length and neoplasia in the *Apc*^{Min} mouse model for colorectal cancer. *Cancer Res* 2010; **70**: 6629–38.
- 8 Fujishita T, Aoki M, Taketo MM. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in *Apc*^{Δ716} mice. *Gastroenterology* 2011; **140**: 1556–63.
- 9 Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. *J Hematol Oncol* 2013; **6**: 27.
- 10 Zhao Y, Adjei AA. The clinical development of MEK inhibitors. *Nat Rev Clin Oncol* 2014; **11**: 385–400.
- 11 Yoshida T, Kakegawa J, Yamaguchi T *et al*. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. *Oncotarget* 2012; **3**: 1533–45.
- 12 Yamaguchi T, Kakefuda R, Tajima N *et al*. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. *Int J Oncol* 2011; **39**: 23–31.
- 13 Kanda Y. Investigation of the freely-available easy-to-use software “EZ” (Easy R) for medical statistics. *Bone Marrow Transplant* 2013; **48**: 452–8.
- 14 Seno H, Oshima M, Ishikawa TO *et al*. Cyclooxygenase 2- and prostaglandin E₂ receptor EP₂-dependent angiogenesis in *Apc*^{Δ716} mouse intestinal polyps. *Cancer Res* 2002; **62**: 506–11.
- 15 Oshima M, Murai N, Kargman S *et al*. Chemoprevention of intestinal polyposis in the *Apc*^{Δ716} mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. *Cancer Res* 2001; **61**: 1733–40.
- 16 Sonoshita M, Takaku K, Sasaki N *et al*. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in *Apc*^{Δ716} knockout mice. *Nat Med* 2001; **7**: 1048–51.
- 17 Lee SH, Hu LL, Gonzalez-Navajas J *et al*. ERK activation drives intestinal tumorigenesis in *Apc*^{min/+} mice. *Nat Med* 2010; **16**: 665–700.
- 18 Dove WF, Clipson L, Gould KA *et al*. Intestinal neoplasia in the *Apc*^{Min} mouse: independence from the microbial and natural killer (*beige* locus) status. *Cancer Res* 1997; **57**: 812–4.
- 19 Xiao H, Yin W, Khan MA *et al*. Loss of single immunoglobulin interleukin-1 receptor-related molecule leads to enhanced colonic polyposis in *Apc*^{min} mice. *Gastroenterology* 2010; **139**: 574–85.
- 20 Dennis KL, Wang Y, Blatner NR *et al*. Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. *Cancer Res* 2013; **73**: 5905–13.
- 21 Grivennikov SI, Wang K, Mucida D *et al*. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. *Nature* 2012; **491**: 254–8.
- 22 Serebrennikova OB, Tsatsanis C, Mao C *et al*. Tpl2 ablation promotes intestinal inflammation and tumorigenesis in *Apc*^{min} mice by inhibiting IL-10 secretion and regulatory T-cell generation. *Proc Natl Acad Sci U S A* 2012; **109**: E1082–91.
- 23 Borsig L, Wolf MJ, Roblek M, Heikenwalder M. Inflammatory chemokines and metastasis-tracing the accessory. *Oncogene* 2014; **33**: 3217–24.
- 24 McClellan JL, Davis JM, Steiner JL *et al*. Intestinal inflammatory cytokine response in relation to tumorigenesis in the *Apc*^{Min/+} mouse. *Cytokine* 2012; **57**: 113–9.
- 25 McClellan JL, Davis JM, Steiner JL *et al*. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G1087–95.
- 26 D’Angelo G, Struman I, Martial J, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. *Proc Natl Acad Sci U S A* 1995; **92**: 6374–8.
- 27 Takahashi O, Komaki R, Smith PD *et al*. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. *Clin Cancer Res* 2012; **18**: 1641–54.
- 28 Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. *Oncogene* 2010; **29**: 781–8.

- 29 Xie W, Herschman H. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. *J Biol Chem* 1996; **271**: 31742–8.
- 30 Sheng H, Williams S, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. *J Biol Chem* 1998; **273**: 22120–7.
- 31 Frungieri MB, Albrecht M, Raemsch R, Mayerhofer A. The action of the mast cell product tryptase on cyclooxygenase-2 (COX2) and subsequent fibroblast proliferation involves activation of the extracellular signal-regulated kinase isoforms 1 and 2 (erk1/2). *Cell Signal* 2005; **4**: 525–33.
- 32 Flaherty KR, Robert C, Hersey P *et al*. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med* 2012; **367**: 107–14.
- 33 Holderfield M, Nagel TE, Stuart DD. Mechanism and consequence of RAF kinase activation by small-molecule inhibitors. *Br J Cancer* 2014; **111**: 640–5.
- 34 Escuin-Ordinas H, Atefi M, Fu Y *et al*. COX-2 inhibition prevents appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. *Mol Oncol* 2014; **8**: 250–60.

Supporting Information

Additional supporting information may be found in the online version of this article:

Data S1. Materials and methods.

Fig. S1. Co-immunostaining analyses for identification of stromal cells that show ERK activation.

Fig. S2. Co-immunostaining analyses for p-ERK and selected stromal cell markers.